Taken together, these data suggest that MCC950 can block NLRP3 inflammasome and NLRC4 inflammasome-mediated IL-1β release in iMGL from healthy controls and SOD1 ALS patients. This evidence concerns the gene NLRP3 and amyotrophic lateral sclerosis.